Nanjing Chia-tai Tianqing Pharmaceutical
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-34
RECRUITING0
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| NTQ5082 100mg qd NCT06764303 |
P2 | Active, not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 24 | 2025-07-08 (+1 mo) |
| NTQ5082 capsules 100 mg NCT06982040 |
P2 | Not yet recruiting | Primary IgA Nephropathy | 80 | 2026-09 |
| NTQ5082 capsules 200 mg NCT07177859 |
P3 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria | 78 | 2026-11 |
| Ramelteon NCT06512363 |
P3 | Not yet recruiting | Chronic Insomnia | 280 | 2026-12 |
| NTB003 NCT07462130 |
P1/2 | Not yet recruiting | Thyroid Eye Disease | 74 | 2027-05-31 |
| NTQ5082 capsules 200 mg NCT07177872 |
P3 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria | 78 | 2028-06 |
| NTQ1062+Fulvestrant NCT07393321 |
P3 | Not yet recruiting | HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer | 210 | 2028-08-31 |